Disparities in the Use of Intravenous t-PA among Ischemic Stroke Patients: Population-based Recent Temporal Trends

J Stroke Cerebrovasc Dis. 2019 May;28(5):1243-1251. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.013. Epub 2019 Feb 8.

Abstract

Objective: To explore a 5-year comparison of disparities in intravenous t-PA (IV t-PA) use among acute ischemic stroke (AIS) patients based on race, gender, age, ethnic origin, hospital status, and geographic location.

Methods: We extracted patients' demographic information and hospital characteristics for 2010 and 2014 from the New York Statewide Planning and Research Cooperative System (SPARCS). We compared disparities in IV t-PA use among AIS patients in 2010 to that in 2014 to estimate temporal trends. Multiple logistic regression was performed to compare disparities based on demographic variables, hospital designation, and geographic location.

Results: Overall, there was approximately a 2% increase in IV t-PA from 2010 to 2014. Blacks were 15% less likely to receive IV t-PA compared to Whites in 2014, but in 2010, there was no difference. Patients aged 62-73 had lower odds of receiving IV t-PA than age group ≤61 in both 2010 and 2014. Designated stroke centers in the Lower New York State region were associated with reduced odds of IV t-PA use in 2010 while those located in the Upper New York State region were associated with increased odds of IV t-PA use in both 2010 and 2014, compared to their respective nondesignated counterparts. Gender, ethnic origin, and insurance status were not associated with IV t-PA utilization in both 2010 and 2014.

Conclusion: Overall IV t-PA utilization among AIS patients increased between 2010 and 2014. However, there are evident disparities in IV t-PA use based on patient's race, age, hospital geography, and stroke designation status.

Keywords: Tissue plasminogen activator; acute ischemic stroke; administrative database; racial disparities; stroke treatment; stroke treatment disparities; trombolysis.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Intravenous
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Brain Ischemia / diagnosis
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / ethnology
  • Databases, Factual
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Health Services Accessibility / trends*
  • Healthcare Disparities / ethnology
  • Healthcare Disparities / trends*
  • Humans
  • Male
  • Middle Aged
  • New York / epidemiology
  • Process Assessment, Health Care / trends*
  • Racial Groups
  • Sex Factors
  • Stroke / diagnosis
  • Stroke / drug therapy*
  • Stroke / ethnology
  • Thrombolytic Therapy / trends*
  • Time Factors
  • Treatment Outcome

Substances

  • Fibrinolytic Agents